Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/60455
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Author: Fellstrom, B.
Jardine, A.
Schmeider, R.
Holdaas, H.
Bannister, K.
Beutler, J.
Chae, D.
Chevaile, A.
Cobbe, S.
Gronhagen-Riska, C.
De Lima, J.
Lins, R.
Mayer, G.
McMahon, A.
Parving, H.
Samuelsson, O.
Sonkodi, S.
Suleymanlar, G.
Tsakiris, D.
Tesar, V.
et al.
Citation: New England Journal of Medicine, 2009; 360(14):1395-1407
Publisher: Massachusetts Medical Soc
Issue Date: 2009
ISSN: 0028-4793
1533-4406
Statement of
Responsibility: 
Bengt C. Fellström... Kym Bannister... et al.
Abstract: Statins reduce the incidence of cardiovascular events in patients at high cardiovascular risk. However, a benefit of statins in such patients who are undergoing hemodialysis has not been proved.We conducted an international, multicenter, randomized, double-blind, prospective trial involving 2776 patients, 50 to 80 years of age, who were undergoing maintenance hemodialysis. We randomly assigned patients to receive rosuvastatin, 10 mg daily, or placebo. The combined primary end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary end points included death from all causes and individual cardiac and vascular events.After 3 months, the mean reduction in low-density lipoprotein (LDL) cholesterol levels was 43% in patients receiving rosuvastatin, from a mean baseline level of 100 mg per deciliter (2.6 mmol per liter). During a median follow-up period of 3.8 years, 396 patients in the rosuvastatin group and 408 patients in the placebo group reached the primary end point (9.2 and 9.5 events per 100 patient-years, respectively; hazard ratio for the combined end point in the rosuvastatin group vs. the placebo group, 0.96; 95% confidence interval [CI], 0.84 to 1.11; P=0.59). Rosuvastatin had no effect on individual components of the primary end point. There was also no significant effect on all-cause mortality (13.5 vs. 14.0 events per 100 patient-years; hazard ratio, 0.96; 95% CI, 0.86 to 1.07; P=0.51).In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. (ClinicalTrials.gov number, NCT00240331.)
Keywords: AURORA Study Group; Humans; Kidney Failure, Chronic; Cardiovascular Diseases; Sulfonamides; Fluorobenzenes; Pyrimidines; Cholesterol; C-Reactive Protein; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Failure; Renal Dialysis; Follow-Up Studies; Prospective Studies; Double-Blind Method; Aged; Aged, 80 and over; Middle Aged; Female; Male; Kaplan-Meier Estimate; Rosuvastatin Calcium
Rights: Copyright © 2009 Massachusetts Medical Society.
RMID: 0020090433
DOI: 10.1056/NEJMoa0810177
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.